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Stable long-term risk of leukaemia in patients with severe
congenital neutropenia maintained on G-CSF therapy
Severe congenital neutropenia (SCN) is a genetically hetero-
geneous disorder of myelopoeisis that is diagnosed clinically
on the basis of an absolute neutrophil count (ANC) persis-
tently below the threshold of 0Æ5 · 109/l, with maturation
arrest of neutrophil precursors in the bone marrow (Ancliff,
2003). Maintenance therapy with granulocyte colony-
stimulating factor (G-CSF) is standard of care to prevent
life-threatening bacterial sepsis (Dale et al, 1993). The success
of G-CSF in averting mortality from sepsis (sepsis deaths)
has unmasked a notable predisposition to myelodysplastic
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Summary
In severe congenital neutropenia (SCN), long-term therapy with granulocyte
colony-stimulating factor (G-CSF) has reduced mortality from sepsis,
revealing an underlying predisposition to myelodysplastic syndrome and
acute myeloid leukaemia (MDS/AML). We have reported the early pattern of
evolution to MDS/AML, but the long-term risk remains uncertain. We
updated a prospective study of 374 SCN patients on long-term G-CSF
enrolled in the Severe Chronic Neutropenia International Registry. Long-
term, the annual risk of MDS/AML attained a plateau (2Æ3%/year after
10 years). This risk now appears similar to, rather than higher than, the risk
of AML in Fanconi anaemia and dyskeratosis congenita.
Keywords: severe congenital neutropenia, acute myeloid leukaemia, myelo-
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syndrome and acute myeloid leukaemia (MDS/AML) (Freed-
man et al, 2000). This susceptibility appears greatest in
patients who require higher doses of G-CSF to achieve an
adequate neutrophil response (Rosenberg et al, 2006).
We previously characterized the natural history of SCN
patients maintained on G-CSF, using prospective observational
study of 374 patients enrolled in the Severe Chronic Neutro-
penia International Registry (SCNIR) (Rosenberg et al, 2006).
At the time of that report, long-term follow-up was limited,
but available data suggested that the risk of MDS/AML in SCN
rose to extraordinary levels, perhaps 8%/year after 12 years on
G-CSF, albeit with a substantial margin for error. The apparent
increase in the hazard curve for MDS/AML has been a cause
for concern among patients and their physicians, and raised
therapeutic and aetiological questions (Dale & Link, 2009).
Hence, obtaining a more precise characterization of the risk
profile is of considerable clinical and scientific importance. To
this end, we updated the prospective follow-up data of the
same cohort to obtain more accurate estimates.
Patients, materials and methods
The Severe Chronic Neutropenia International Registry
We updated prospective follow-up data of 374 well-character-
ized SCN patients on long-term G-CSF enrolled in the SCNIR.
We ascertained event-free time, sepsis deaths, and MDS/AML
events that accrued since our previous report, which ended 26
February 2001, through to 10 July 2009. For purposes of this
analysis, follow-up was censored at the time of bone marrow
transplant. Data on baseline G-CSF dose at month 6 of
treatment was abstracted from registry and medical records,
and converted to units of micrograms per kilogram per day
(lg/kg per d), as described previously (Rosenberg et al, 2006).
Data on mean ANC counts (cells · 109/l) during months 6–18
on treatment were also abstracted. The study was conducted in
accordance with the Declaration of Helsinki under the auspices
of the Human Subjects Committee of the University of
Washington and other participating institutions. Patients
provided informed consent.
Statistical methods
SCN patients are at risk of both MDS/AML and sepsis death,
which we analysed as competing adverse events. The time scale
was years on G-CSF therapy. We obtained flexible and smooth
estimates of the cause-specific hazards of MDS/AML and sepsis
death using spline functions (Rosenberg, 1995). The cumu-
lative incidence of each adverse event was estimated using the
nonparametric maximum likelihood estimator (Gaynor et al,
1993). The effects of baseline G-CSF dose on the hazard of each
adverse event were estimated using Cox proportional hazards
models applied to follow-up from month 6 onwards. All
statistical tests were two-sided. P values £ 0Æ05 were considered
statistically significant.
Results and discussion
The update yielded a total of 3590 person-years of follow-up,
versus 2043 in the prior report (Rosenberg et al, 2006). Follow-
up was censored in 19 patients who received a bone marrow
transplant. There were 849 person-years among 176 patients
treated for 10 or more years; versus just 67 person-years among
60 patients previously. In all, there were 61 MDS/AML events
and 29 sepsis deaths, versus prior totals of 44 and 19,
respectively. After including up-to-date follow-up, the esti-
mated annual hazard of sepsis death remained qualitatively
stable, at 0Æ81%/year [95% confidence interval (CI): 0Æ56 –
1Æ16%/year]. Similarly, during the first 5 years after the start of
G-CSF therapy, the updated estimate of the hazard curve for
MDS/AML showed the same increasing trend as the previous
estimate (Fig 1A). However, in contrast to the prior estimate
(A)
(B)
Fig 1. Hazard rates and cumulative incidence of MDS/AML and sepsis
death in patients with SCN. (A) Annual hazard rates (incidence rate
per year among patients who are still susceptible) for MDS/AML and
sepsis death, by years on therapy with G-CSF. Dot-dash curves (green
for MDS/AML and yellow for sepsis death) show estimates obtained
from prior data (Rosenberg et al, 2006); solid curves (blue for MDS/
AML and grey for sepsis death) show estimates obtained using updated
follow-up. Shaded regions show point-wise 95% confidence envelopes
for new estimates; error bars show point-wise 95% confidence intervals
for previous estimates at selected years. (B) Corresponding estimates of
cumulative incidence (cumulative proportion experiencing each event
as initial cause of failure, in patients at risk of each adverse event), by
years on G-CSF therapy, using updated follow-up (solid curves and
shaded regions), compared with prior data (dot-dash curves and error
bars).
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that showed an increasing trend after year 5 (with a large
margin for error), the updated hazard curve attained a plateau,
with confidence intervals for the new hazard curve consider-
ably narrower than corresponding intervals in our earlier
report (Rosenberg et al, 2006). After 10 years on G-CSF, the
estimated hazard of MDS/AML was 2Æ3%/year (95% CI: 1Æ7–
2Æ9%/year).
Whereas the long-term hazard of MDS/AML now appears
significantly lower than first suggested, substantial numbers of
sepsis deaths and cases of MDS/AML accumulated over time.
After 15 years on G-CSF, the cumulative incidence was 10%
(95% CI: 6–14%) for sepsis death and 22% (95% CI: 17–28%)
for MDS/AML Fig 1B). In the initial dataset, the correspond-
ing estimates of cumulative incidence attained similar values
earlier, 8% and 21% at 10 years, respectively.
With additional follow-up, the association of G-CSF dose at
6 months with the relative hazard of MDS/AML became more
strongly statistically significant [P = 0Æ003 vs. P = 0Æ024; the
hazard of MDS/AML increased by 1Æ24-fold (95% CI: 1Æ08-
1Æ43-fold) per doubling of the G-CSF dose]. In contrast, the
association of G-CSF dose at 6 months with the relative hazard
of sepsis death was slightly attenuated [P = 0Æ053 vs. P = 0Æ039;
the hazard of sepsis death increased by 1Æ25-fold (95% CI: 1Æ00
– 1Æ56-fold) per doubling].
As in the previous analysis, the subset of patients who failed
to achieve a mean ANC count at or above the median for the
cohort (2Æ188 · 109/l) despite doses of G-CSF at or above the
median (8 lg/kg per d), were at elevated risk of both sepsis
death and MDS/AML, compared with patients who achieved a
good response at a lower dose (i.e. median ANC count above
2Æ188 · 109/l on G-CSF below 8 lg/kg per d). In the low-risk
group, the cumulative incidence after 15 years on G-CSF was
5% (95% CI: 0–12%) for sepsis death and 15% (95% CI: 4–
25%) for MDS/AML (Fig 2A), versus 18% (95% CI: 7–28%)
and 34% (95% CI: 21–47%), respectively, in the high-risk
group (Fig 2B).
This analysis incorporates extended follow-up of the largest
existing cohort of patients with SCN, which has allowed us to
estimate the long-term risks with greater precision. Overall,
comparisons of the new results (2009) with the old (2001) are
very consistent. However, there is one important exception: in
all patients combined, the hazard of MDS/AML now appears
to be around 2Æ3%/year after 10 years on G-CSF, substantially
below the range of 4–12%/year suggested by prior unstable
data.
This is good news for patients and their physicians. Also, the
reduced hazard estimate for MDS/AML helps resolve an
aetiological conundrum. From a molecular perspective, it was
not entirely clear why susceptibility to leukaemia appeared
higher in SCN than in other high-risk inherited bone marrow
failure syndromes, including the DNA repair disorder of
Fanconi anaemia (FA) (Rosenberg et al, 2003) or the telomere
maintenance syndrome of dyskeratosis congenita (DC) (Alter
et al, 2009). Indeed, the high incidence of leukaemic transfor-
mation in SCN had raised concerns that G-CSF may promote
malignant clones (Donadieu et al, 2005). In light of these new
data, it now appears that the rate of MDS/AML in SCN is
qualitatively quite similar to the rate of AML in both FA and
DC. Furthermore, a plateau is now seen in SCN, similar to that
for FA.
The positive news in this report must be put in perspective.
Although the hazard curve for MDS/AML in SCN now appears
to plateau, the cumulative incidence still attains high levels,
albeit more slowly. Hence, it is imperative that all patients
continue to be closely monitored for leukaemic transfor-
mation. Furthermore, the risks and benefits of early haema-
topoietic stem cell transplantation should be evaluated for
the subset of patients who respond poorly to a high dose of
G-CSF.
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